Revenue Growth Driven by Core Portfolio
Total revenue increased 4.4% year-over-year to $6.96B in Q1 FY2026, compared to $6.67B in the prior-year period, reflecting continued demand for Gilead's antiviral and oncology franchises.
GILEAD SCIENCES, INC. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Gilead Sciences delivered a strong Q1 FY2026 with revenue up 4.4% to $6.96B, net income surging 53.7% to $2.02B, and operating cash flow jumping 44.8% to $2.54B, driven by lower cost of revenue and improved operating leverage.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue increased 4.4% year-over-year to $6.96B in Q1 FY2026, compared to $6.67B in the prior-year period, reflecting continued demand for Gilead's antiviral and oncology franchises.
Cost of revenue declined 6.2% year-over-year to $1.45B from $1.54B, meaningfully expanding gross profit and contributing to an operating margin improvement of approximately 3.6 percentage points to 37.2%.
Net income rose 53.7% to $2.02B from $1.32B in the prior-year quarter, with diluted EPS climbing 54.8% to $1.61, indicating strong bottom-line leverage on modest top-line growth.
Revenue
$6.96B
++4.39% YoY
EPS (Basic)
$1.63
++53.77% YoY
Operating Income
$2.59B
++15.60% YoY
Add GILD to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.